Skip to content

Timing of high-efficacy therapy initiation in multiple sclerosis: a multicenter real-world analysis from Argentina.

Nov 2026 · Multiple Sclerosis and Related Disorders · Vol 116, pp. 108039 · 0 citations · 26 references
Medicine

Abstract

Early initiation of high-efficacy therapies (HETs) in relapsing-remitting multiple sclerosis (RRMS) is associated with improved long-term outcomes, yet real-world treatment trajectories may not reflect this paradigm. We aimed to quantify delays in diagnosis and treatment initiation in RRMS and assess whether these differ across first-line strategies in Argentina.

Methods

We conducted a multicenter registry-based study including treatment-naïve RRMS patients from the Argentine Multiple Sclerosis Registry (RelevarEM). Three intervals were evaluated: symptom-to-diagnosis/treatment indication (T1), diagnosis/treatment indication-to-treatment initiation (T2), and symptom-to-treatment initiation (T3). Delays were compared across oral, injectable, and high-efficacy therapies using descriptive analyses and multivariable accelerated failure time models adjusted for demographic, clinical, and healthcare-related factors.

Results

A total of 389 patients were included. The interval from diagnosis/treatment indication to treatment initiation (T2) was comparatively similar across groups (approximately 1-2 months). In contrast, the symptom-to-treatment interval (T3) was longer among patients initiating HETs versus oral therapies (adjusted median 9.13 vs 2.58 months; +6.54 months), with the excess time concentrated predominantly before the recorded diagnosis/treatment-indication milestone. Sensitivity analyses suggested heterogeneity within HETs.

Conclusion

These findings suggest that the longer time to HET initiation is primarily attributable to the interval preceding the recorded diagnosis/treatment-indication milestone, whereas the subsequent interval to treatment initiation was comparatively similar across treatment classes.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.